Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Sulfoxide SCHEMBL7542256 | 0.90 | MEN1 (0.51) | MEN1KMT2AKDM4EALDH1A1AGTR1 | |
| SCHEMBL3184435 | 0.85 | TSHR (0.70) | MEN1KMT2AKDM4EPOLBTSHR | |
| SCHEMBL11639337 | 0.85 | SRD5A2 (0.67) | MEN1KMT2AKDM4EALDH1A1AGTR1 | |
| SCHEMBL28814684 | 0.80 | CES2 (0.63) | TSHRSRD5A2CES2CES1NPC1 | |
| SCHEMBL5199645 | 0.79 | CES2 (0.73) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL2783342 | 0.78 | NAPRT (0.65) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL906513 | 0.75 | TSHR (0.68) | MEN1KMT2AKDM4ETSHRHPGD | |
| SCHEMBL8055116 | 0.74 | CES2 (0.57) | MEN1KMT2AKDM4EPOLBTSHR | |
| SCHEMBL7088584 | 0.74 | TSHR (0.50) | MEN1KMT2AKDM4ETSHRHPGD | |
| SCHEMBL3136894 | 0.74 | TSHR (0.59) | MEN1KMT2AKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7235658-B2 | Imidazol derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20060122207-A1 | Imidazol derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. | 2006-06-08 | — | — | US | disclosed |
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1261602-B1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1263753-B1 | IMIDAZOL DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-14 | — | — | US | disclosed |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | GAIBA ALESSANDRA (GB) | 2003-07-17 | — | — | US | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0854870-A4 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153588-A1 | Imidazol derivatives as raf kinase inhibitors | RAF1, BRAF, ARAF | MEN1 2970/4885KMT2A 1681/4885KDM4E 2417/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | MEN1 720/4885KMT2A 1485/4885KDM4E 2180/4885 |
| US-20060122207-A1 | Imidazol derivatives as Raf kinase inhibitors | RAF1, BRAF, ARAF | MEN1 2229/4885KMT2A 2021/4885KDM4E 2709/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | MEN1 1768/4885KMT2A 1766/4885KDM4E 2137/4885 |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | MEN1 2375/4885KMT2A 1156/4885KDM4E 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.